|
(Vancouver, BC — Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, has closed its previously announced public offering of 1,789,900 units for total gross proceeds before expenses of CDN$5.1 million. The Company intends to use the net proceeds of the offering for general corporate purposes.
Versant Partners Inc. was the placement agent for the offering in Canada and other jurisdictions outside the United States. The units were offered in the United States directly by the Company. The offering was completed pursuant to a base shelf prospectus filed in Canada and a registration statement filed with the Securities and Exchange Commission (SEC), which became effective on November 4, 2010. ThinkEquity LLC acted as a financial advisor to Tekmira.
A prospectus supplement relating to the offering was filed on SEDAR and with the SEC. The base prospectus, as supplemented, can be obtained from the SEC’s website at https://www.sec.gov or from SEDAR at https://www.sedar.com. A copy of the base prospectus and prospectus supplement may also be obtained from Tekmira Pharmaceuticals Corporation at 100-8900 Glenlyon Parkway, Burnaby, British Columbia, V5J 5J8.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
|